Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has added a new report providing a competitor analysis in the development pipeline of novel insulin-based products for treatment of type 1 and 2 diabetes.
“Insulin: Competitor Analysis” which is available at http://www.piribo.com/
The first Indian company is conducting clinical trials in the US with its rhu insulin and even plans to develop and launch a biosimilar insulin analog in the Western countries upon patent expiry in 2014. Three companies in off-patent countries have locally produced insulin analogs either in the market or in pre-registration phases.
Authors of the report note that the next generations of insulin will be "tailored" insulin and oral insulin. They further note that after the failure of inhaled insulin (only one clinical stage project left), most of the R&D efforts are now made on oral insulin products.
The pipeline of oral insulin shows at least seven different oral insulin formulations in clinical development, and at least six in preclinical development. The first oral insulin product is already marketed and in advanced registration in many countries. Further six different projects with non-injectable drug delivery of insulin are in clinical development:
The report “Insulin: Competitor Analysis” is available in pdf format from Piribo: http://www.piribo.com/
Piribo product ID: LME060
